CGYN18151 / NRG-GY012 / Richard MooreResearch Question:
How well does olaparib and cediranib maleate work in treating patients with endometrial
cancer that has come back (recurrent), does not respond to treatment (refractory),
or has spread to other places in the body (metastatic)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase II trial studies the effects of the combination of olaparib and durvalumab,
cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating
patients with endometrial cancer that has come back (recurrent) or does not respond
to treatment (refractory). Olaparib, cediranib, and capivasertib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab
is a monoclonal antibody that may interfere with the ability of tumor cells to grow
and spread. Testing the combinations may lower the chance of endometrial cancer growing
or spreading compared to usual care.
Study Reference #: CGYN18151
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search